Results 161 to 170 of about 2,198 (193)

Dynamic risk stratification-guided management of medullary thyroid carcinoma: integrating surgical precision with RET-targeted therapies and molecular surveillance. [PDF]

Int J Surg
Zhang J, Dionigi G, Kim HY, Sun H, Li C.
europepmc   +1 more source

Neck Lump and Cough: The Uncommon Encounter. [PDF]

Oman Med J
Mukherjee R, Thakur RS, Guha S, Roychowdhury A.   +3 more
europepmc   +1 more source

Correction to : Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study’’ by Subbiah et al. Thyroid 2024;34(1):26–40 ; doi: 10.1089/thy.2023.0363

openalex   +1 more source

Novosti v sistemskem zdravljenju diferenciranega raka ščitnice [PDF]

Grašič-Kuhar, Cvetka
core   +1 more source

Protein-Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection. [PDF]

Molecules
Petsas E, Kiouri DP, Georgiou N, Siasos G, Mavromoustakos T, Chasapis CT.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pralsetinib

Reactions Weekly
  +13 more sources

Pralsetinib: First Approval

Drugs, 2020
Pralsetinib (GAVRETO™, Blueprint Medicines Corporation) is a selective rearranged during transfection (RET) inhibitor being developed for the treatment of various solid tumours. RET is a well described proto-oncogene present in multiple cancers including non-small cell lung cancer (NSCLC), papillary thyroid cancer, and medullary thyroid carcinoma (MTC).
openaire   +2 more sources